Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of PDR001 in advanced neuroendocrine tumors
NL-OMON46949Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of spartalizumab, sponsored by Novartis. Started Jul 2017; status: active, not recruiting.
02
Drugs
spartalizumab
Beyond the preview
Go deeper on NL-OMON46949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46949.